Cantor Fitzgerald Analysts Lower Earnings Estimates for PRE

Prenetics Global Limited (NASDAQ:PRE) – Analysts at Cantor Fitzgerald cut their FY2024 earnings per share estimates for shares of Prenetics Global in a note issued to investors on Thursday, March 6th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($3.52) for the year, down from their prior estimate of ($3.30). Cantor Fitzgerald currently has a “Overweight” rating and a $9.00 price objective on the stock. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Cantor Fitzgerald also issued estimates for Prenetics Global’s FY2025 earnings at ($2.12) EPS.

Prenetics Global Stock Down 3.4 %

Shares of Prenetics Global stock opened at $4.37 on Monday. Prenetics Global has a twelve month low of $2.85 and a twelve month high of $7.84. The business has a 50-day moving average price of $5.40 and a 200 day moving average price of $4.98. The firm has a market cap of $53.29 million, a PE ratio of -1.09 and a beta of -0.31.

Institutional Investors Weigh In On Prenetics Global

A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in shares of Prenetics Global Limited (NASDAQ:PRE) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned about 0.10% of Prenetics Global at the end of the most recent reporting period. Institutional investors and hedge funds own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.